AAPL 223.5389 -0.0943% MSFT 393.45 -0.4327% NVDA 114.83 -4.8554% GOOGL 167.85 -1.5889% GOOG 170.11 -1.551% AMZN 202.31 -1.6528% META 614.88 -1.825% AVGO 182.79 -2.9056% LLY 844.495 -0.9216% TSLA 276.155 -4.1594% TSM 175.64 -2.9077% V 347.08 0.7138% JPM 253.94 1.1189% UNH 521.325 1.5377% NVO 72.62 -1.3315% WMT 85.375 0.7256% LVMUY 129.14 -0.0077% XOM 118.96 2.0328% LVMHF 638.0 -1.6131% MA 550.46 0.9722%

2Seventy Bio Inc

Healthcare US TSVT

4.955USD
0.005(0.10%)

Last update at 2025-03-26T16:44:00Z

Day Range

4.954.97
LowHigh

52 Week Range

1.5312.69
LowHigh

Fundamentals

  • Previous Close 4.95
  • Market Cap219.50M
  • Volume602512
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-203.58000M
  • Revenue TTM71.20M
  • Revenue Per Share TTM1.39
  • Gross Profit TTM -183.45800M
  • Diluted EPS TTM-4.13

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -254.15300M -292.21300M -120.11400M -320.59400M -199.74900M
Minority interest - - - - -
Net income -254.14401M -292.21300M -138.17000M -323.34100M -199.74900M
Selling general administrative 79.68M 93.51M 90.90M 81.65M 53.63M
Selling and marketing expenses - - - - -
Gross profit 65.28M 52.01M 242.73M 41.32M 53.69M
Reconciled depreciation 11.53M 16.35M 13.19M 12.59M 13.35M
Ebit -262.90800M -292.21300M -144.63800M -337.97300M -181.26400M
Ebitda -251.14300M 16.06M -113.39400M -322.63900M -167.91900M
Depreciation and amortization 11.77M 16.35M 31.24M 15.33M 13.35M
Non operating income net other 6.05M 21.65M - - -
Operating income -262.90800M -313.94800M -144.63800M -337.97300M -203.42600M
Other operating expenses 354.40M 0.37M 392.76M 382.27M 255.01M
Interest expense 8.51M 276.45M 0.00000M 0.00000M 15.49M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 2.93M 0.09M - 0.00000M -
Net interest income 2.93M 0.09M 0.00000M 0.00000M -15.48600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.00899M -313.65579M 18.06M 2.75M 19.16M
Total revenue 91.50M 54.52M 248.12M 44.30M 54.58M
Total operating expenses 328.19M 368.47M 387.36M 379.29M 254.12M
Cost of revenue 26.22M 2.52M 5.40M 2.98M 0.89M
Total other income expense net 8.76M 313.66M 24.52M 17.38M 16.16M
Discontinued operations - - - - -
Net income from continuing ops -254.15300M -292.21300M -120.11400M -320.59400M -199.74900M
Net income applicable to common shares -254.15300M -292.21300M -120.11400M -320.59400M -199.74900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 565.43M 656.66M 759.67M 312.62M 314.95M
Intangible assets 6.59M 7.30M 9.89M 5.64M 9.41M
Earning assets - - - - -
Other current assets 20.78M 0.01M 26.51M 14.41M 13.42M
Total liab 310.13M 346.20M 399.85M 237.99M 271.26M
Total stockholder equity 255.30M 310.47M 359.82M 74.63M 43.69M
Deferred long term liab - - - - -
Other current liab 25.69M 58.42M 77.59M 52.58M 63.22M
Common stock 0.00500M 0.00400M 0.00200M 74.63M 43.69M
Capital stock 0.00500M 0.00400M 0.00200M - -
Retained earnings -511.21700M -293.64700M -39.49400M - -
Other liab - 7.40M 29.02M 49.83M 45.60M
Good will 0.00000M 12.06M 12.06M 13.13M 13.13M
Other assets - 38.39M -0.00007M 8.26M 14.05M
Cash 74.96M 71.03M 130.41M -127.60300M -133.57500M
Cash and equivalents - - - - -
Total current liabilities 59.78M 79.79M 98.39M 75.87M 103.40M
Current deferred revenue 15.40M 3.00M 5.00M 0.82M 8.47M
Net debt 181.72M 199.14M 151.80M 255.21M 267.15M
Short term debt 12.66M 11.16M 9.77M 15.31M 11.32M
Short long term debt - - - - -
Short long term debt total 256.67M 270.17M 282.21M 127.60M 133.57M
Other stockholder equity 766.72M 606.99M 400.03M 74.63M 43.69M
Property plant equipment - 55.73M 34.91M 260.48M 257.52M
Total current assets 237.76M 300.88M 291.56M 25.10M 20.84M
Long term investments 4.82M 1.41M 97.12M - -
Net tangible assets - 291.11M 337.87M 55.86M 21.16M
Short term investments 142.03M 195.24M 134.64M - -
Net receivables 13.41M 20.96M 17.00M 10.69M 7.43M
Long term debt - - - - -
Inventory -13.41100M 13.64M -114.11900M 127.60M -
Accounts payable 6.03M 7.21M 6.02M 7.15M 20.39M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.20400M -2.87700M -0.71200M - -
Additional paid in capital - - - - -
Common stock total equity - 0.00400M 0.00200M - -
Preferred stock total equity - - - - -
Retained earnings total equity - -293.64700M -39.49400M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 36.42M 38.39M 38.59M 8.26M 14.05M
Deferred long term asset charges - - - - -
Non current assets total 327.66M 355.78M 468.11M 287.52M 294.11M
Capital lease obligations 256.67M 270.17M 282.21M 127.60M 133.57M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 34.54M 15.41M -22.26100M -59.76500M -50.82700M
Change to liabilities -7.78300M 15.73M -4.92300M -2.06300M -39.64200M
Total cashflows from investing activities 11.70M 15.41M -22.26100M -59.76500M -50.82700M
Net borrowings - - - - -1.01700M
Total cash from financing activities 166.23M 354.89M 90.05M 267.72M 197.04M
Change to operating activities -13.43600M 9.16M -10.54600M 37.21M 35.82M
Net income -254.15300M -292.21300M -120.11400M -320.59400M -199.74900M
Change in cash -59.20800M 163.27M 90.05M 267.72M 197.04M
Begin period cash flow 163.27M 0.00000M 0.00000M 0.00000M 0.00000M
End period cash flow 104.06M 163.27M 0.00000M 0.00000M 0.00000M
Total cash from operating activities -237.13400M -207.03400M -67.79300M -207.95700M -146.21500M
Issuance of capital stock 165.53M - - - -
Depreciation 11.53M 16.35M 13.19M 12.59M 13.35M
Other cashflows from investing activities - -8.00000M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 165.53M 354.89M - - -
Other cashflows from financing activities 0.70M 348.35M 90.05M 267.72M 198.06M
Change to netincome 41.36M 55.50M 54.60M 64.91M 44.01M
Capital expenditures 22.84M 19.57M 22.26M 59.77M 50.83M
Change receivables - - - - -
Cash flows other operating -28.08800M -2.39600M - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -59.20800M 163.27M - - -
Change in working capital -35.87100M 13.33M -15.46900M 35.14M -3.81800M
Stock based compensation 41.04M 54.63M 61.00M 62.05M 40.80M
Other non cash items 0.32M 0.87M -6.39500M 2.86M 3.21M
Free cash flow -259.97600M -226.60900M -90.05400M -267.72200M -197.04200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TSVT
2Seventy Bio Inc
0.005 0.10% 4.96 - - 2.58 1.01 2.97 -1.4451
NVO
Novo Nordisk A/S
-1.44 1.96% 72.16 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
-1.28 1.75% 72.07 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-7.84 1.54% 501.20 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
0.08 0.01% 634.22 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

2Seventy Bio Inc

60 Binney Street, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Mr. Nick Leschly Pres, CEO & Director 1973
Mr. William D. Baird III Chief Financial Officer 1972
Ms. Nicola H. Heffron Chief Operating Officer 1973
Ms. Susan Abu-Absi Ph.D. Chief Technology & Manufacturing Officer NA
Dr. Philip D. Gregory D. Phil., DPHIL Chief Scientific Officer 1971
Ms. Teresa L. Jurgensen J.D. VP, Gen. Counsel & Corp. Sec. NA
Ms. Kathleen A. Wilkinson Head of People & Culture 1972
Mr. Kevin Chin M.D., M.S. Head of Clinical Devel. NA
Mr. Steven Shamah Ph.D. Head of Oncology Research NA
Ms. Jenn Snyder Head of Corp. Affairs NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.